Literature DB >> 12504926

The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level.

Juliano Ferreira1, Maria M Campos, Ronaldo Araújo, Michael Bader, João B Pesquero, João B Calixto.   

Abstract

The mechanisms by which kinins induce hyperalgesia in the spinal cord were investigated by using B(1) or B(2) knockout mice in conjunction with kinin selective agonists and antagonists. The i.t. administration of the kinin B(2) receptor agonists, bradykinin (BK) or Tyr(8)-BK produced dose-related thermal hyperalgesia evaluated in the hot-plate test. BK-induced hyperalgesia was abolished by the B(2) receptor antagonist Hoe 140. The i.t. injection of the kinin B(1) receptor agonists, des-Arg(9)-bradykinin (DABK) or des-Arg(10)-kallidin (DAKD) also caused dose-related thermal hyperalgesia. Different from the B(2) agonists, the i.t. injection of DABK or DAKD caused a weak, but prolonged hyperalgesia, an effect that was blocked by the B(1) receptor antagonist des-Arg(9)-[Leu(8)]-bradykinin (DALBK). The i.t. injection of BK caused thermal hyperalgesia in wild-type mice (WT) and in the B(1) receptor knockout mice (B(1)R KO), but not in the B(2) receptor knockout mice (B(2)R KO). Similarly, the i.t. injection of DABK elicited thermal hyperalgesia in WT mice, but not in B(1)R KO mice. However, DABK-induced hyperalgesia was more pronounced in the B(2)R KO mice when compared with the WT mice. The i.t. injection of Hoe 140 or DALBK inhibited the second phase of formalin (F)-induced nociception. Furthermore, i.t. Hoe 140, but not DALBK, also inhibits the first phase of F response. Finally, the i.t. injection of DALBK, but not of Hoe 140, inhibits the long-term thermal hyperalgesia observed in the ipsilateral and in contralateral paws after intraplantar injection with complete Freund's adjuvant. These findings provide evidence that kinins acting at both B(1) and B(2) receptors at the spinal level exert a critical role in controlling the nociceptive processing mechanisms. Therefore, selective kinin antagonists against both receptors are of potential interest drugs to treat some pain states.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12504926     DOI: 10.1016/s0028-3908(02)00311-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  21 in total

Review 1.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

2.  Involvement of the kallikrein-kinin system in a model of hyperalgesia in low kallikrein rats.

Authors:  M V Varoni; D Palomba; S Gianorso; V Anania; M P Demontis
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

3.  Kinin B1 receptor deficiency attenuates cisplatin-induced acute kidney injury by modulating immune cell migration.

Authors:  Gabriel R Estrela; Frederick Wasinski; Danilo C Almeida; Mariane T Amano; Angela Castoldi; Carolina C Dias; Denise M A C Malheiros; Sandro S Almeida; Edgar J Paredes-Gamero; João B Pesquero; Carlos C Barros; Niels O S Câmara; Ronaldo C Araújo
Journal:  J Mol Med (Berl)       Date:  2013-12-20       Impact factor: 4.599

4.  Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission.

Authors:  Haibin Wang; Tatsuro Kohno; Fumimasa Amaya; Gary J Brenner; Nobuko Ito; Andrew Allchorne; Ru-Rong Ji; Clifford J Woolf
Journal:  J Neurosci       Date:  2005-08-31       Impact factor: 6.167

5.  Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins.

Authors:  Indiara Brusco; Cássia Regina Silva; Gabriela Trevisan; Camila de Campos Velho Gewehr; Flávia Karine Rigo; Lidia La Rocca Tamiozzo; Mateus Fortes Rossato; Raquel Tonello; Gerusa Duarte Dalmolin; Daniela de Almeida Cabrini; Marcus Vinícius Gomez; Juliano Ferreira; Sara Marchesan Oliveira
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

6.  Select G-protein-coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and β-arrestin 1 pathway.

Authors:  Nitish Mittal; Kristofer Roberts; Katsuri Pal; Laurent A Bentolila; Elissa Fultz; Ani Minasyan; Catherine Cahill; Amynah Pradhan; David Conner; Kathryn DeFea; Christopher Evans; Wendy Walwyn
Journal:  Cell Rep       Date:  2013-11-14       Impact factor: 9.423

7.  Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity.

Authors:  Tatsuro Kohno; Haibin Wang; Fumimasa Amaya; Gary J Brenner; Jen-Kun Cheng; Ru-Rong Ji; Clifford J Woolf
Journal:  J Neurosci       Date:  2008-04-23       Impact factor: 6.167

8.  The role of kinin B1 and B2 receptors in the scratching behaviour induced by proteinase-activated receptor-2 agonists in mice.

Authors:  Robson Costa; Marianne N Manjavachi; Emerson M Motta; Denise M Marotta; Luiz Juliano; Hugo A Torres; João B Pesquero; João B Calixto
Journal:  Br J Pharmacol       Date:  2010-01-08       Impact factor: 8.739

9.  Potentiation of glutamatergic synaptic transmission by protein kinase C-mediated sensitization of TRPV1 at the first sensory synapse.

Authors:  Parul Sikand; Louis S Premkumar
Journal:  J Physiol       Date:  2007-03-15       Impact factor: 5.182

10.  Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin.

Authors:  Sébastien Talbot; Patrick Théberge-Turmel; Dalinda Liazoghli; Jacques Sénécal; Pierrette Gaudreau; Réjean Couture
Journal:  J Neuroinflammation       Date:  2009-03-26       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.